Tucson startup looks to human trials for drug to treat lung inflammation
Aqualung Therapeutics, a Tucson-based drug startup headed by a University of Arizona pulmonologist, has won a major investment
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer TUCSON, AZ / ACCESSWIRE / January
A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression
A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression Abstract Prostate cancer (PCa) is the
Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine Nov/Dec Issue
Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension Jiwang Chen 1, Justin R Sysol 1, Sunit Singla 1, Shuangping Zhao 1, Aya Yamamura 1, Daniela Valdez-Jasso 1, Taimur
Novel Mechanism for Nicotinamide Phosphoribosyltransferase Inhibition of TNF-a–mediated Apoptosis in Human Lung Endothelial Cells
Novel Mechanism for Nicotinamide Phosphoribosyltransferase Inhibition of TNF-α–mediated Apoptosis in Human Lung Endothelial Cells Radu C. Oita,1Sara M. Camp,1Wenli